Literature DB >> 15830575

Topical phenylephrine in the treatment of radiation-induced faecal incontinence.

S Badvie1, H J N Andreyev.   

Abstract

AIMS: Acute bowel toxicity after pelvic radiotherapy is defined as occurring within 3 months of the start of treatment; chronic gastrointestinal toxicity may continue after the acute phase or start after a latent period. One in five patients develop chronic faecal incontinence affecting quality of life; how best to treat these patients is not known. This retrospective study aimed to determine the effects of a new agent, phenylephrine gel, in the treatment of chronic radiation-induced faecal incontinence.
MATERIALS AND METHODS: Patients prescribed phenylephrine gel for new-onset faecal incontinence after radiotherapy were identified from our database of patients treated in a specialist radiation-induced bowel damage clinic since 2000. Changes in the level of faecal incontinence were assessed using the Vaizey faecal incontinence scoring system before and after treatment.
RESULTS: Fifteen patients (nine men and six women) of mean age 70.5 years (standard deviation 8.2, age range 56-82 years) were treated with phenylephrine gel a median of 43 months after completing radiotherapy. The median Vaizey score before treatment with phenylephrine gel was 17 (interquartile range [IQR] 14-20) and after treatment was 14 (IQR 11-18) (P = 0.005). The median length of treatment with phenylephrine gel was 28 days (IQR 28-365). Scores improved in 11 out of 15 patients; four out of 15 patients showed substantial improvements of 7 or more points; and seven patients considered the gel helpful.
CONCLUSION: Topical phenylephrine gel for the treatment of radiation-induced faecal incontinence has not been previously reported. This small, retrospective study suggests that it may help most patients and, in some, the improvement may be substantial. However, larger placebo-controlled prospective studies are required.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15830575     DOI: 10.1016/j.clon.2004.07.011

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  8 in total

1.  Investigation of the distribution and function of alpha-adrenoceptors in the sheep isolated internal anal sphincter.

Authors:  S J Rayment; T Eames; J A D Simpson; M R Dashwood; Y Henry; H Gruss; A G Acheson; J H Scholefield; V G Wilson
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Administration of a Sol-Gel Formulation of Phenylephrine Using Low-Temperature Hollow Microneedle for Treatment of Intermittent Fecal Incontinence.

Authors:  Hyunji Lee; Jung-Hwan Park; Jung Ho Park
Journal:  Pharm Res       Date:  2017-11-27       Impact factor: 4.200

Review 3.  Medical management of fecal incontinence in challenging populations: a review.

Authors:  David Lee; Gaurav Arora
Journal:  Clin Colon Rectal Surg       Date:  2014-09

Review 4.  Faecal incontinence: Current knowledges and perspectives.

Authors:  Alban Benezech; Michel Bouvier; Véronique Vitton
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

5.  Gastrointestinal complications of pelvic radiotherapy: are they of any importance?

Authors:  J Andreyev
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

6.  Local transdermal delivery of phenylephrine to the anal sphincter muscle using microneedles.

Authors:  Changyoon Baek; MeeRee Han; Junhong Min; Mark R Prausnitz; Jung-Hwan Park; Jung Ho Park
Journal:  J Control Release       Date:  2011-05-07       Impact factor: 9.776

7.  The efficacy and adverse effects of topical phenylephrine for anal incontinence after low anterior resection in patients with rectal cancer.

Authors:  Jun-Seok Park; Sung-Bum Kang; Duck-Woo Kim; Hyung-Wook Namgung; Hye-Lin Kim
Journal:  Int J Colorectal Dis       Date:  2007-06-12       Impact factor: 2.571

8.  Characterization of the alpha1-adrenoceptor subtype mediating contractions of the pig internal anal sphincter.

Authors:  Ka Mills; N Hausman; R Chess-Williams
Journal:  Br J Pharmacol       Date:  2008-06-02       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.